TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City, June 2-4, 2026.
Rhea-AI Summary
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City, June 2-4, 2026.
A fireside chat is scheduled for Wednesday, June 3, 2026, at 11:40 AM ET, with a live webcast available on the company’s investor website Events page.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TGTX
On May 28, the day this news came out, TGTX closed 0.97% below the previous close.
Data tracked by StockTitan Argus for the May 28 session.
Key Figures
- Fireside chat date
- June 3, 2026
- Scheduled Jefferies Global Healthcare Conference appearance
- Fireside chat time
- 11:40 AM ET
- Start time of Jefferies conference fireside chat
- Conference dates
- June 2–4, 2026
- Jefferies Global Healthcare Conference in New York City
Historical Context
-
Positive Phase 3 ENHANCE topline results for BRIUMVI in relapsing MS.
-
Multiple BRIUMVI data presentations at the 2026 CMSC MS conference.
-
Strong Q1 2026 results, raised 2026 revenue guidance, and capital actions.
-
Precision BioSciences Q1 2026 update with cash runway and pipeline progress.
-
Scheduling of TG Therapeutics’ Q1 2026 earnings call and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026. The fireside chat is scheduled to take place on Wednesday, June 3, 2026, at 11:40 AM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at https://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.